|
Market Report
|
HIV-AIDS - Pipeline Assessment and Market Forecasts to 2016
GlobalData, the industry analysis specialist, has released its latest report, "HIV-AIDS - Pipeline Assessment and Market Forecasts to 2016" which provides the key data, information and analysis on the HIV/AIDS market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with HIV/AIDS, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the HIV/AIDS market.
|
|
Read more...
|
|
|
Market Report
|
|
Depression - Generic induced brand erosion leads to market decline
The depression market was valued at around $11.04 billion in 2007 across the seven major markets. Following marginal growth to 2011 ($12.01 billion), the market is forecast to decline in value through to 2017 ($9.81 billion) when brand erosion due to generic incursion affecting all major drug classes used to treat depression finally outweighs the success of reformulations and follow-on products.
|
|
Read more...
|
|
|
Market Report
|
|
Antidepressants - Novel mechanism offers hope in depressed market
With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial potential and the most promising candidate to date is Servier and Novartis's melatonin agonist and serotonin antagonist Valdoxan (agomelatine).
|
|
Read more...
|
|
|
Market Report
|
The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities
Since 2000, oncology has become one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents. Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.
|
|
Read more...
|
|
|
Market Report
|
Innovation and market growth opportunities in bone metastases and emerging supportive care challenges
Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases.
|
|
Read more...
|
|
|
Market Report
|
Innovations in Injectables: Current and emerging technologies to improve drug delivery
This report evaluates the current and evolving technologies used for injectable drug delivery, the key therapuetic areas, the barriers and driving forces for this market, the competitive landscape is analysed according the technology type, and key pipeline companies and products are examined. Leading companies in the injectable drug delivery market are also profiled.
|
|
Read more...
|
|
|
Market Report
|
The Private Health Insurance Market in Europe: Future trends, emerging opportunities and key players
This report reviews their role in the major European markets and provides an insight into trends in their coverage of health benefits and products. It includes overall trends and profiles of leading insurers, provides an indication of future developments within the sector and highlights potential opportunities for pharmaceutical and diagnostic companies to work with private insurers.
|
|
Read more...
|
|
|
Market Report
|
Analyzing Market Trends and Regulatory Impacts
With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible.
|
|
Read more...
|
|
|
Market Report
|
Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets
The 2009/10 influenza H1N1 pandemic has boosted awareness of respiratory viral infections. Stockpiling has been pivotal for the strong growth of the influenza antivirals market, with 2009 seven major market sales reaching $1,772m. As the pandemic recedes, other promising targets in the sector include respiratory syncytial virus (RSV), parainfluenza virus (PIV) and human metapneumovirus (hMPV).
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 10 - 18 of 366 |
Farmavita.Net Journal 
